KR20140043720A - 길항성 dr3 리간드 - Google Patents

길항성 dr3 리간드 Download PDF

Info

Publication number
KR20140043720A
KR20140043720A KR1020137021269A KR20137021269A KR20140043720A KR 20140043720 A KR20140043720 A KR 20140043720A KR 1020137021269 A KR1020137021269 A KR 1020137021269A KR 20137021269 A KR20137021269 A KR 20137021269A KR 20140043720 A KR20140043720 A KR 20140043720A
Authority
KR
South Korea
Prior art keywords
ser
antibody
leu
gly
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137021269A
Other languages
English (en)
Korean (ko)
Inventor
메테 달 안데르센
페데르 리스비 뇌르드비
크리스티안 키예르가르드
수산나 네데르가르드 그렐
알브레흐트 그룰러
옌스 부차르트
헨릭 수네 안데르센
쇠렌 파드키예르
제스퍼 카스트루프
카타리나 하칸손
라르스 호르눔
비르기테 프리드리히센
도리트 바운스가르드
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20140043720A publication Critical patent/KR20140043720A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137021269A 2011-03-01 2012-03-01 길항성 dr3 리간드 Withdrawn KR20140043720A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11156416 2011-03-01
EP11156416.7 2011-03-01
US201161448827P 2011-03-03 2011-03-03
US61/448,827 2011-03-03
PCT/EP2012/053539 WO2012117067A1 (en) 2011-03-01 2012-03-01 Antagonistic dr3 ligands

Publications (1)

Publication Number Publication Date
KR20140043720A true KR20140043720A (ko) 2014-04-10

Family

ID=44210048

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137021269A Withdrawn KR20140043720A (ko) 2011-03-01 2012-03-01 길항성 dr3 리간드

Country Status (12)

Country Link
US (4) US9737612B2 (cg-RX-API-DMAC7.html)
EP (1) EP2681237A1 (cg-RX-API-DMAC7.html)
JP (1) JP6215056B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140043720A (cg-RX-API-DMAC7.html)
CN (1) CN103517918A (cg-RX-API-DMAC7.html)
BR (1) BR112013022052A2 (cg-RX-API-DMAC7.html)
CA (1) CA2828464A1 (cg-RX-API-DMAC7.html)
IL (1) IL227535A0 (cg-RX-API-DMAC7.html)
MX (1) MX2013009859A (cg-RX-API-DMAC7.html)
RU (1) RU2013141079A (cg-RX-API-DMAC7.html)
WO (1) WO2012117067A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201306110B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140287952A1 (en) * 2013-03-15 2014-09-25 Alderbio Holdings Llc Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
WO2015036553A1 (en) 2013-09-16 2015-03-19 Novo Nordisk Health Care Ag Thiol functionalized polymers
CA2924520C (en) * 2013-11-01 2023-09-26 Ibc Pharmaceuticals, Inc. Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
AU2015242752A1 (en) * 2014-04-04 2016-10-20 Kyowa Hakko Kirin Co., Ltd. Anti-death receptor 3 (DR3) antagonistic antibodies with reduced agonistic activity
EP3137495A4 (en) * 2014-04-28 2017-11-15 The National Institute for Biotechnology in the Negev, Ltd. Variants of dr3 and use thereof
EP3572502B1 (en) * 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
EP3860653A1 (en) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and systems for controlling the agonistic properties of antibody variable domains by light
CN111808183B (zh) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 一种靶向CD47的高亲和力SIRPα突变体及其融合蛋白
EP4507779A1 (en) 2022-04-14 2025-02-19 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
JP7849919B2 (ja) * 2022-06-17 2026-04-22 セレクシン インコーポレイテッド ヒトdr3に特異的に結合する抗体及びその用途
CN116223818B (zh) * 2023-05-09 2023-07-21 四川大学华西医院 Dr3蛋白检测试剂在制备筛查aecopd的试剂盒的用途及筛查aecopd的试剂盒
CN116514983B (zh) * 2023-06-02 2025-05-23 安徽金百奥生物科技有限公司 一种靶向dr3胞外域的纳米抗体及其应用
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use
GB202315963D0 (en) 2023-10-18 2023-11-29 Cancer Research Tech Ltd Binding molecules
AU2025213136A1 (en) 2024-01-24 2026-07-16 Shattuck Labs, Inc. Antibodies that bind tnfrsf25

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
BR9910568A (pt) 1998-04-30 2001-09-11 Tanox Inc Anticorpos agonistas de receptor de g-csf e processo de seleção para os mesmos
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
AU4478200A (en) 1999-04-22 2000-11-10 Human Genome Sciences, Inc. Death domain containing receptors
AU784504B2 (en) * 1999-11-19 2006-04-13 Thomas V. Tittle TR3-specific binding agents and methods for their use
US6638906B1 (en) * 1999-12-13 2003-10-28 Nobex Corporation Amphiphilic polymers and polypeptide conjugates comprising same
EP1263788A2 (en) 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
WO2002040680A2 (en) 2000-11-17 2002-05-23 The Burnham Institute Death domain proteins
PL366469A1 (en) 2001-04-05 2005-02-07 Immuno-Biological Laboratories Co, Ltd. Anti-osteopontin antibody and use thereof
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
US20090317388A1 (en) * 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
DK1919954T3 (en) * 2005-08-30 2017-01-30 Univ Miami Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
US20110195048A1 (en) 2008-10-08 2011-08-11 Podack Eckhard R Regulation of lymphocytes and uses therefor
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3

Also Published As

Publication number Publication date
US20170305994A1 (en) 2017-10-26
CA2828464A1 (en) 2012-09-07
JP2014509325A (ja) 2014-04-17
RU2013141079A (ru) 2015-04-10
BR112013022052A2 (pt) 2016-11-22
US20130336984A1 (en) 2013-12-19
US8765130B2 (en) 2014-07-01
MX2013009859A (es) 2014-02-28
US20130330360A1 (en) 2013-12-12
ZA201306110B (en) 2014-04-30
JP6215056B2 (ja) 2017-10-18
US20140294853A1 (en) 2014-10-02
US9713644B2 (en) 2017-07-25
WO2012117067A1 (en) 2012-09-07
EP2681237A1 (en) 2014-01-08
IL227535A0 (en) 2013-09-30
US9737612B2 (en) 2017-08-22
CN103517918A (zh) 2014-01-15

Similar Documents

Publication Publication Date Title
US9713644B2 (en) Antagonistic DR3 ligands
KR102483016B1 (ko) FcRn 항체 및 이의 사용 방법
JP6286532B2 (ja) 抗cd38抗体及び弱毒化インターフェロンアルファ−2bとの融合物
TW201839014A (zh) 抗-ilt4抗體及抗原結合片段
AU2025275202A1 (en) Interleukin-2 Mutant And Fusion Protein Thereof
CA3002588C (en) Single-chain cd137-receptor agonist proteins
CN115368458A (zh) 抗cd73抗体及其应用
JP2017512772A (ja) Lg1〜3に特異的な抗ラミニン4抗体
KR20230166120A (ko) 새로운 tnfr2 결합 분자
KR20230079397A (ko) 신규 항-클라우딘18 항체
EP3112462A1 (en) Novel bispecific antibody binding to human tlr2 and human tlr4
US20250074999A1 (en) Antibodies against lypd3
WO2025034715A1 (en) Gucy2c antibodies and uses thereof
JP2024505563A (ja) Gitrアンタゴニスト及びその使用方法
JP6853392B2 (ja) 抗cd38抗体及び弱毒化インターフェロンアルファ−2bとの融合物
AU2012222342A1 (en) Antagonistic DR3 ligands
JP6648171B2 (ja) 抗cd38抗体及び弱毒化インターフェロンアルファ−2bとの融合物
TW202334218A (zh) 新型抗lag3抗體
HK40097196A (en) Novel anti-cldn18 antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130812

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20150202

WITB Written withdrawal of application